Press Release

Morrison & Foerster Advises A-Share Listed Shanghai Dazhong in HK$1.7 Billion H-Share IPO

05 Dec 2016

HONG KONG (December 5, 2016) – Morrison & Foerster’s Hong Kong capital markets team is representing  Shanghai Dazhong Public Utilities (Group) Co., Ltd. in relation to its HK$1.7 billion H-share initial public offering (IPO),  which listed today on the Hong Kong Stock Exchange.

Shanghai Dazhong is a leading public utility service provider in Shanghai that complements its operations with strategic and financial investments in its associated companies in public utility and other industries. It is the largest gas supplier in Shanghai, and is also an A-share listed company on the Shanghai Stock Exchange. Shanghai Dazhong will use most of the proceeds for expansion, including investment in gas supply businesses and acquisition of gas suppliers.

Ven Tan, managing partner of Morrison & Foerster’s Hong Kong office and head of the Hong Kong capital markets team, led the deal team, which also included Of Counsels Samuel Ng and Wang Yu.

“We continue to see a steady stream of A-share listed companies coming to Hong Kong for a dual listing to extend their global reach. We are fortunate to have represented Shanghai Dazhong in its dual listing in Hong Kong and add them to our growing list of dual-listed clients which include China CNR, Angang Steel, Shanghai Petrochemical, Fosun Pharma, China CITIC Bank, Dalian Port and Goldwind. We see this growing client base as an important source for compliance work and other outbound transactional deals,” said Mr. Tan.

Morrison & Foerster is one of the leading capital markets firms in Hong Kong, as well as Greater China. The most respected ranking publications, such as Chambers Global, Chambers Asia, IFLR, and Asia-Pacific Legal 500, have consistently ranked the firm highly for its premier capital markets offerings. Prior to this IPO, Morrison & Foerster’s Hong Kong capital markets team most recently completed the HK$650 million IPO by Jacobson Pharma Corporation Limited, the largest generic drug company in Hong Kong, on the Hong Kong Stock Exchange.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.